Law Firm Brower Piven Announces Investigation of Cornerstone Therapeutics, Inc. Proposed Acquisition
Law Firm Brower Piven Announces Investigation of Cornerstone Therapeutics, Inc. Proposed Acquisition
STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Cornerstone Therapeutics, Inc. ("Cornerstone" or the "Company") (NAS: CRTX) and other violations of state law by the board of directors of Cornerstone relating to the proposed acquisition of the Company by Chiesi Farmaceutici S.p.A. The firm's investigation seeks to determine, among other things, whether the board of directors of Cornerstone breached their fiduciary duties by failing to maximize shareholder value.
According to the press release announcing the proposed acquisition, Cornerstone shareholders will receive $9.50 per share in cash for each share of Cornerstone common stock they own. According to Yahoo! Finance, Cornerstone common stock has traded above the deal price everyday this month.
If you currently own common stock of Cornerstone and would like to learn more about the investigation being conducted by Brower Piven, you may email or call Brower Piven, who will, without obligation or cost to you, attempt to answer your questions. You may contact Brower Piven by email at hoffman@browerpiven.com, by calling (410) 415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and other class action cases of over 60 years.
Brower Piven, A Professional Corporation
Stevenson, Maryland
Charles J. Piven, 410-415-6616
hoffman@browerpiven.com
KEYWORDS: United States North America Maryland
INDUSTRY KEYWORDS:
The article Law Firm Brower Piven Announces Investigation of Cornerstone Therapeutics, Inc. Proposed Acquisition originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
